Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice
- PMID: 24485896
- DOI: 10.1016/j.antiviral.2014.01.013
Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice
Abstract
Coxsackievirus B3 (CVB3) is an important cause of acute and chronic viral myocarditis, and dilated cardiomyopathy (DCM). Although vaccination against CVB3 could significantly reduce the incidence of serious or fatal viral myocarditis and various other diseases associated with CVB3 infection, there is currently no vaccine or therapeutic reagent in clinical use. In this study, we contributed towards the development of a CVB3 vaccine by establishing an efficient and scalable ion exchange chromatography-based purification method for CVB3 virus and baculovirus-insect cell-expressed CVB3 virus-like particles (VLPs). This purification system is especially relevant for vaccine development and production on an industrial scale. The produced VLPs were characterized using a number of biophysical methods and exhibited excellent quality and high purity. Immunization of mice with VLPs elicited a strong immune response, demonstrating the excellent vaccine potential of these VLPs.
Keywords: CVB3; Ion exchange chromatography; VLP.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis.Vaccine. 2012 Mar 16;30(13):2301-8. doi: 10.1016/j.vaccine.2012.01.061. Epub 2012 Jan 31. Vaccine. 2012. PMID: 22306858
-
Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine.Antiviral Res. 2019 Nov;171:104595. doi: 10.1016/j.antiviral.2019.104595. Epub 2019 Sep 3. Antiviral Res. 2019. PMID: 31491431
-
Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.Vaccine. 2011 Sep 16;29(40):6894-902. doi: 10.1016/j.vaccine.2011.07.049. Epub 2011 Jul 29. Vaccine. 2011. PMID: 21803097
-
Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease.Int J Med Microbiol. 2008 Jan;298(1-2):127-34. doi: 10.1016/j.ijmm.2007.08.010. Epub 2007 Sep 25. Int J Med Microbiol. 2008. PMID: 17897883 Review.
-
Manipulating intestinal immunity and microflora: an alternative solution to viral myocarditis?Future Microbiol. 2012 Oct;7(10):1207-16. doi: 10.2217/fmb.12.96. Future Microbiol. 2012. PMID: 23030425 Review.
Cited by
-
Cellular N-myristoyltransferases play a crucial picornavirus genus-specific role in viral assembly, virion maturation, and infectivity.PLoS Pathog. 2018 Aug 6;14(8):e1007203. doi: 10.1371/journal.ppat.1007203. eCollection 2018 Aug. PLoS Pathog. 2018. PMID: 30080883 Free PMC article.
-
A novel rat CVB1-VP1 monoclonal antibody 3A6 detects a broad range of enteroviruses.Sci Rep. 2018 Jan 8;8(1):33. doi: 10.1038/s41598-017-18495-4. Sci Rep. 2018. PMID: 29311608 Free PMC article.
-
Environmental Factors Associated With Type 1 Diabetes.Front Endocrinol (Lausanne). 2019 Aug 28;10:592. doi: 10.3389/fendo.2019.00592. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31555211 Free PMC article. Review.
-
Vaccines against Group B Coxsackieviruses and Their Importance.Vaccines (Basel). 2023 Jan 27;11(2):274. doi: 10.3390/vaccines11020274. Vaccines (Basel). 2023. PMID: 36851152 Free PMC article. Review.
-
Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus.Nat Rev Endocrinol. 2022 Aug;18(8):503-516. doi: 10.1038/s41574-022-00688-1. Epub 2022 Jun 1. Nat Rev Endocrinol. 2022. PMID: 35650334 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources